However, based on our subgroup analyses, we found a consistent reduction in anemia risk from SGLT2 inhibitor treatment in patients across different levels of kidney function, and this observation was in line with the results from the post hoc analyses of the CREDENCE and DAPA-CKD trials.14,15 Altogether, these findings may reinforce the proposed mechanism of anemia improvement from SGLT2 inhibitor use through regulation of the hypoxia-inducible factor system and stimulation of EPO secretion.16,60 Future studies are warranted to confirm our observations and prove this hypothesis. Here, EPO is linked to chronic kidney disease.